

Copper(I)-Catalyzed N-O Bond Formation through Vinyl Nitrene-Mediated Pathway under Mild Conditions

Feifei Wu, Min Zhang, Wei Zhou, Wanzhi Chen, Miaochang Liu, and Huayue Wu

J. Org. Chem., **Just Accepted Manuscript** • DOI: 10.1021/acs.joc.8b00605 • Publication Date (Web): 14 May 2018

Downloaded from <http://pubs.acs.org> on May 15, 2018

Just Accepted

“Just Accepted” manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides “Just Accepted” as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. “Just Accepted” manuscripts appear in full in PDF format accompanied by an HTML abstract. “Just Accepted” manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). “Just Accepted” is an optional service offered to authors. Therefore, the “Just Accepted” Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the “Just Accepted” Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these “Just Accepted” manuscripts.

Copper(I)-Catalyzed N-O Bond Formation through Vinyl Nitrene-Mediated Pathway under Mild Conditions


Feifei Wu,[†] Min Zhang,[†] Wei Zhou,[†] and Wanzhi Chen^{*,†}, Miaochang Liu^{*,‡} and Huayue Wu[‡]

[†]Department of Chemistry, Zhejiang University, Hangzhou 310027, China

[‡]College of Chemistry and Materials Engineering, Wenzhou University, Wenzhou, 325027, China.

E-mail: chenwzz@zju.edu.cn; mcl@wzu.edu.cn

ABSTRACT: Copper(I)-catalyzed N-O bond formation reactions through vinyl nitrene-mediated pathway were described. The reactions of *N*-alkoxybenzamides and 2*H*-azirines afforded α -amino oxime ethers in good to excellent yields at room temperature, which involved the cleavage of C-N and N-O bonds, and the construction of new N-O and C-N bonds. It offers an efficient, regio- and stereoselective synthetic route for α -amino oxime ethers.



INTRODUCTION

Nitrogen-oxygen single bonds have been found in many biologically active compounds.¹ They exist in both aromatic *N*-heterocycles such as isoxazoles, benzisoxazoles, furazans, 1,2-azines, 1,2-oxazines, and nonaromatic chain compounds like *N*-hydroxylamine, oximes, and *N*-oxides. These compounds show promising biological activities, such as antifungal, anti-inflammatory and analgesic, as well as anti-histamine effects.² For example, Orysastrobin is used to control the leaf and panicle blast (*Magnaporthe grisea*) and sheath blight (*Thanatephorus cucumeris*) in rice.³ SCH 206272 is a potent and orally active tachykinin NK1, NK2, and NK3 receptor antagonist (Figure 1).⁴




Figure 1. Representative examples of α -amino oxime ethers.


Typically, the N-O moieties are constructed from the derivation of the starting materials with pre-existing N-O bonds such as hydroxylamines and nitro compounds. Although amine *N*-oxides and pyridine *N*-oxides are easily accessible through direct oxidation with peroxides,⁵ metal-catalyzed direct N-O coupling has been scarcely studied. Usually, the known N-O bond formation approaches involve oxidative N-O coupling. Oxidation of β -aminoketones by $\text{PhI}(\text{OAc})_2$ could afford isoxazolo[3,4-d]primidine-4,6-dione derivatives due to N-O bond formation.⁶ Cu-catalyzed oxidative N-O bond formation between amides and organic nitriles led to 1,2,4-oxadiazoles using O_2 as the oxidant.⁷ FeBr_2 catalyzed reaction of aryl and vinyl azides with ketone resulted in 2,1-benzisoxazoles.⁸ It was believed that azide was activated via coordination of the terminal N-atom to iron(II), then the activated azide was attacked by O-atom of ketone, and finally N_2 lost. Reactions of *ortho*-hydroxyaryl N-H ketimines with NCS or NaClO yielded 2- and 3-substituted

1
2
3 benzisoxazoles through N–Cl imine intermediate.⁹ Reactions of aldehydes or ketones
4 with TMSN₃ in the presence of ZrCl₄ or TfOH afforded benzisoxazoles after nitrogen
5 extrusion via an intramolecular nucleophilic substitution of azido methanolate
6 complex or imine diazonium ion.¹⁰ The above described synthetic approaches are
7 restricted to synthesize heterocyclic compounds containing N–O bonds. The
8 construction of N–O bonds in chain compounds has seldom been studied.
9
10
11
12
13

14 Transition metal catalyzed reactions of 2*H*-azirines¹¹ have been used to
15 synthesize indoles,¹² amides,¹³ oxime ethers,¹⁴ and 1,2,3-triazole derivatives¹⁵. These
16 transformations usually involve nitrene intermediate. We envisioned that *N*-alkoxyl
17 benzamide containing a fissionable N–O bond would react with vinyl nitrene to form a
18 new N–O bond.¹⁶ Herein we describe copper(I)-catalyzed difunctionalization of
19 2*H*-azirines offering α -amino oxime ethers through vinyl nitrene-mediated pathway
20 under mild conditions in good to excellent yields.¹⁷
21
22
23
24
25
26

27 RESULTS AND DISCUSSION

28
29 **Table 1.** Optimization of Reaction Conditions^a




Entry	Catalyst (10 mol%)	Base (1 equiv.)	Solvent	Yield ^b (%)
1	Pd(OAc) ₂	-	DCE	84
2	Pd(OAc) ₂	K ₂ CO ₃	DCE	99
3	{Cp*RhCl ₂ } ₂	K ₂ CO ₃	DCE	75
4	Pd(OAc) ₂	K ₂ CO ₃	methanol	0
5	MnBr(CO) ₅	K ₂ CO ₃	DCE	54
6	CuI	K ₂ CO ₃	DCE	99(97)
7	-	K ₂ CO ₃	DCE	0
8 ^c	CuI	K ₂ CO ₃	DCE	93
9 ^d	CuI	K ₂ CO ₃	DCE	89
10	Cu(OAc) ₂	K ₂ CO ₃	DCE	87
11	CuCl ₂	K ₂ CO ₃	DCE	92
12	Cu(OTf) ₂	K ₂ CO ₃	DCE	68
13	CuI	K ₂ CO ₃	DMF	7
14	CuI	K ₂ CO ₃	Toluene	75

^a Reaction conditions: **1a** (0.2 mmol), **2a** (0.4 mmol), catalyst (0.02 mmol), base (0.2 mmol) in 2 mL of solvent at room temperature for 12 h; ^b Yields determined by ¹H NMR analysis using CH₂Br₂ as the internal standard and isolated yields shown in parentheses; ^c CuI (5 % mmol); ^d CuI (2 % mmol).

Initially, we started our work by taking *N*-methoxybenzamide **1a** and 3-phenyl-2*H*-azirine **2a** as the model substrates using Pd(OAc)₂ catalyst to optimize the reaction conditions. The optimization results were shown in Table 1. At a loading of 10 mol% of the palladium catalyst, we were pleased to find that α -amino oxime ether **3a** was obtained in 84% yield in DCE at room temperature based on ¹H NMR analysis (Table 1, entry 1). Addition of K₂CO₃ could further promote the reaction, and **3a** could be almost quantitatively obtained (Table 1, entry 2). {Cp*RhCl₂}₂ was also active, and **3a** was afforded in 75% yield under the same conditions (Table 1, entry 3). When protonic solvent methanol was used, the reaction was totally inhibited (Table 1,

entry 4). $\text{MnBr}(\text{CO})_5$ could also catalyse the reaction, and **3a** was obtained in a moderate yield (Table 1, entry 5). To our surprise, the cheap copper(I) salt was quite efficient to give **3a** in a quantitative yield (Table 1, entry 6). Without metal catalysts the reaction did not proceed (Table 1, entry 7). When 2-5 mol% of CuI was used, the yield of **3** was slightly decreased (Table 1, entries 8 and 9). Other copper catalysts such as $\text{Cu}(\text{OAc})_2$, CuCl_2 , and $\text{Cu}(\text{OTf})_2$ are less efficient than CuI (Table 1, entries 10-12). The ^1H NMR spectral analysis showed that in solution only the *anti* isomer was formed. The structures of **3a** and **3b** were further identified by X-ray crystallography, which were presented in Figure S1 in the Supporting Information.

Table 2. Scope of 2*H*-azirines^{a,b}





^aReaction conditions: **1** (0.2 mmol), **2a** (0.4 mmol), CuI (0.02 mmol), K_2CO_3 (0.2 mmol) in 2 mL of DCE at room temperature for 12 h. ^b Isolated yields.

With optimized conditions in hand, we continued to explore the substrate scope of

the reaction. Various *N*-alkoxylamides containing both electron-donating and electron-withdrawing groups were examined (Table 2). The results showed that both electron-donating and electron-withdrawing groups at their aromatic rings were tolerated. *N*-Methoxybenzamides bearing methyl groups at *o*-, *m*-, and *p*-positions were quite reactive, and in such cases **3** were obtained in more than 83% yields. *N*-Methoxybenzamides containing halogen substituents are also good reaction partners giving α -amino oxime ethers **3e**, **3f**, and **3g** in good to excellent yields. Reactions of two *N*-methoxynaphthalenecarboxamides **1m** and **1n** with *2H*-azirine afforded **3m** and **3n** in 61% and 88% yields, respectively. Unexpectedly, the substrates having 4-*t*-Bu and 4-OMe are less reactive, and the corresponding products **3c** and **3d** were produced in only 60% and 52% yields, respectively. Heterocyclic compounds containing N, O, and S did not show negative effect, and **3o**, **3p**, and **3q** were isolated in 62, 93, and 80% yields, respectively. Aliphatic amides *N*-methoxy-2-methyl-2-phenylpropanamide **1r** and *N*-methoxycyclopropanecarboxamide **1s** could participate in the reaction, and **3r** and **3s** were isolated in moderate yields. Bulkier *N*-*t*-butoxybenzamide **1u** also showed good reactivity, and the reactivity was not affected by the steric hindrance.


Table 3. Scope of *2H*-azirines^{a,b}





^aReaction conditions: **1a** (0.2 mmol), **2** (0.4 mmol), CuI (0.02 mmol), K₂CO₃ (0.2 mmol) in 2 mL of DCE at room temperature for 12 h. ^bIsolated yield.

Subsequently, the reactions of various 2*H*-azirines **2** with *N*-methoxybenzamide **1a** were further investigated (Table 3). Generally, 3-phenyl-2*H*-azirine derivatives having an alkyl, F, Br substituents proceeded smoothly to give the desired products in good to excellent yields. However, the chlorine-containing 2*H*-azirine showed relatively lower activity, and **3w** was isolated in only 46% yield. In addition, the disubstituted azirine, 2,3-diphenyl-2*H*-azirine **1z**, gave the corresponding products **3z** in 70% yield. In addition, 3-alkyl-2*H*-azirine was also compatible, and **3aa** was afforded from (3-methyl-2*H*-azirine-2-yl)(phenyl)methanone in 53% yield.




Scheme 1. Gram scale and further transformation experiments


The optimized reaction conditions were suitable for gram-scale preparation. For

example, when 10 mol% CuI was used, the reaction of **2b** (0.990 g) and **1a** (0.702 g) was conducted at room temperature for twelve hours, the desired product **3b** (1.236 g) was isolated in 73% yield. We found that treatment of **3b** with Cu(OAc)₂·2H₂O at 100 °C resulted in *anti-syn* isomerization, and the *syn* isomer (*Z*)-*N*-(2-(methoxyimino)-2-phenylethyl)-4-methylbenzamide **4** was obtained in 28% yield, and **3b** was recovered in 68% yield (Scheme 1). Treatment of **3b** with CF₃COOH resulted in isomerization and partial hydrolysis to 4-methyl-*N*-(2-oxo-2-phenylethyl)benzamide **5**. In the presence of CF₃COOH or BF₃, only the hydrolysed product α -aminoketone **5** was isolated in 53% yield.


Free radical trapping



Nucleophilic agent trapping



Substrate control



Scheme 2. Control experiments.




Figure 2. A possible reaction pathway

To explore the possible mechanism, a few control experiments were performed under the standard conditions (Scheme 2). In the presence of a radical scavenger 2,2,6,6-tetramethyl-1-piperidinyloxy (TEMPO), the reaction of **1a** and **2a** afforded **3a** in 82% yield, indicating that the radical pathway could be excluded. When 2 equiv. of *t*-BuONa was added, the reaction of **1a** and **2a** gave **3a** in 94% yield. The reaction of **1a** and **2a** in the presence of 2 equiv. of 4-(*tert*-butyl)benzamide did not give the mixtures of **3a** and **3c**. In addition, the reaction of benzamide and **2a** in the presence of 2 equiv. of CH₃ONa did not result in the formation of **3a**. These results illustrate that the reaction is not proceeded via substitution reaction. It was also found that when *N*-methoxy-*N*-methylbenzamide was used in the reaction, no product was generated. The reaction of *N*-phenylacetamide and phthalimide with azirine did not occur under the same reaction conditions, and the starting materials could be recovered, indicating that the reaction was not initiated by nucleophilic addition of amidate to C=N bond and subsequent ring-opening. Based on these observations, a possible reaction pathway was proposed and depicted in Figure 2. In the presence of a base, Cu(I) *N*-alkoxylamidate complex **I** would be expected upon deprotonation of *N*-alkoxylamide. Intramolecular oxidative addition of N-O bond toward Cu(I) would occur to give Cu(III) intermediate **II**.¹⁸ The Cu(III) species was captured by 2*H*-azirine **2**, and subsequent rearrangement would result in the formation of Cu(nitrene) amidate intermediate **III**. Insertion of nitrene into the Cu-O bond gave

1
2
3 species **IV**. Intermediate **V** was afforded through 1,3-migration.^{19,20} Reductive
4 elimination would finally generate product **3**.
5
6

7 In conclusion, the reaction of *N*-methoxybenzamides and *2H*-azirines was
8 developed leading to α -amino oxime ethers in good to excellent yields under mild
9 conditions. It involved copper(I)-catalyzed N-O bond formation through vinyl
10 nitrene-mediated pathway. The α -amino oxime ethers could be afforded at 100%
11 atom economy with excellent regioselectivity and stereoselectivity. Further
12 exploration of a detailed mechanism and relevant reactions involving *2H*-azirines is
13 currently underway.
14
15
16
17
18

19 **EXPERIMENTAL SECTION**

20 **General remarks**

21 Reagents were obtained from commercial sources and used without further
22 purification. Solvents were dried and stored over 4 Å molecular sieves under nitrogen.
23 Reactions were carried out under nitrogen using standard Schlenk technique unless
24 otherwise noted. Flash column chromatography was performed on silica gel 300 and
25 thin-layer chromatography on GF 254 plates. Melting points were determined with an
26 Electrothermal apparatus and are uncorrected. ¹H NMR and ¹³C NMR spectra were
27 recorded in CDCl₃ at 400 and 100 MHz, respectively, using the solvents as internal
28 standard. Multiplicities are abbreviated as follows: s = singlet, d = doublet, t = triplet,
29 q = quartet, m = multiplet, dd = doublet of doublet, dt = doublet of triplet, br = broad.
30 *J*-values are in Hz. Commercially obtained reagents were used without further
31 purification. *N*-Methoxybenzamides **1** and *2H*-azirines **2** were prepared according to
32 literatures.^{21,22}
33
34
35
36
37
38
39
40
41
42
43
44

45 **General procedure for synthesis of 3.** To a flame-dried flask were added
46 *N*-alkoxylamide **1** (0.2 mmol, 1.0 equiv), CuI (0.02 mmol, 0.1 equiv) and K₂CO₃ (0.2
47 mmol 1.0 equiv). Then, DCE (2.0 mL) and **2** (0.4 mmol, 2.0 equiv) were added
48 subsequently. The reaction mixture was stirred for 12 hours at room temperature. The
49 crude product was purified by silica gel chromatography (petroleum ether:ethyl
50 acetate = 3:1) to afford the desired product **3**.
51
52
53
54
55

56 (*E*)-*N*-(2-(methoxyimino)-2-phenylethyl)benzamide (**3a**): White solid; mp: 129-130
57
58
59
60

°C; yield: 52 mg, 97%; ¹H NMR (400 MHz, CDCl₃): δ = 7.80-7.78 (m, 2H), 7.55-7.37 (m, 8H), 7.07 (br, 1H), 4.51 (d, *J* = 4.8 Hz, 2H), 3.92 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 167.2, 151.7, 134.3, 131.6, 131.5, 129.7, 128.6, 128.4, 128.0, 127.0, 62.5, 43.4; HRMS (EI-TOF) *m/z*: [M]⁺ calcd for C₁₆H₁₆N₂O₂ 268.1212; Found 268.1215.

(*E*)-*N*-(2-(methoxyimino)-2-phenylethyl)-4-methylbenzamide (**3b**): White solid; mp: 95-97 °C; yield: 53 mg, 94%; ¹H NMR (400 MHz, CDCl₃): δ = 7.69 (d, *J* = 7.6 Hz, 2H), 7.54-7.52 (m, 2H), 7.43-7.38 (m, 3H), 7.24 (d, *J* = 7.6 Hz, 2H), 7.00 (br, 1H), 4.51 (d, *J* = 4.8 Hz, 2H), 3.92 (s, 3H), 2.40 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 167.1, 151.8, 142.0, 131.6, 131.5, 129.7, 129.3, 128.4, 128.0, 127.0, 62.4, 43.3, 21.5; HRMS (EI-TOF) *m/z*: [M]⁺ calcd for C₁₇H₁₈N₂O₂ 282.1368; Found 282.1371.

(*E*)-4-(*tert*-butyl)-*N*-(2-(methoxyimino)-2-phenylethyl)benzamide (**3c**): White solid; mp: 108-110 °C; yield: 39 mg, 60%; ¹H NMR (400 MHz, CDCl₃): δ = 7.73 (d, *J* = 8.4 Hz, 2H), 7.55-7.52 (m, 2H), 7.47-7.38 (m, 2H), 7.03 (br, 1H), 4.51 (d, 4.8 Hz, 2H), 3.91 (s, 3H), 1.33 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ = 167.1, 155.0, 151.8, 131.6, 131.5, 129.7, 128.4, 128.0, 126.9, 125.6, 62.4, 43.3, 34.9, 31.2; HRMS (EI-TOF) *m/z*: [M]⁺ calcd for C₂₀H₂₄N₂O₂ 324.1838; Found 324.1834.

(*E*)-4-methoxy-*N*-(2-(methoxyimino)-2-phenylethyl)benzamide (**3d**): White solid; mp: 106-108 °C; yield: 31 mg, 52%; ¹H NMR (400 MHz, CDCl₃): δ = 7.76 (m, 2H), 7.55-7.52 (m, 2H), 7.44-7.36 (m, 3H), 6.95-6.92 (m, 3H), 4.50 (d, *J* = 4.8 Hz, 2H), 3.92 (s, 3H), 3.85 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 166.7, 162.3, 151.9, 131.6, 129.7, 128.8, 128.4, 128.0, 126.6, 113.8, 62.4, 55.4, 43.3; HRMS (EI-TOF) *m/z*: [M]⁺ calcd for C₁₇H₁₈N₂O₃ 298.1317; Found 298.1313.

(*E*)-4-fluoro-*N*-(2-(methoxyimino)-2-phenylethyl)benzamide (**3e**): White solid; mp: 111-113 °C; yield: 50 mg, 87%; ¹H NMR (400 MHz, CDCl₃): δ = 7.82-7.78 (m, 2H), 7.54-7.52 (m, 2H), 7.44- 7.32 (m, 3H), 7.11 (t, *J* = 8.4 Hz), 7.03 (b, 1H), 4.5 (d, *J* = 4.8 Hz, 2H), 3.92 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 166.1, 164.8 (d, *J*_{CF} = 250.4 Hz), 151.6, 131.5, 130.5 (d, *J*_{CF} = 2.9 Hz), 129.7, 129.4 (d, *J*_{CF} = 9.0 Hz), 128.4, 128.0, 115.7 (d, *J*_{CF} = 21.9 Hz), 62.5, 43.4; ¹⁹F NMR (376 MHz, CDCl₃): δ = -108.1; HRMS (EI-TOF) *m/z*: [M]⁺ calcd for C₁₆H₁₅FN₂O₂ 286.1118; Found 286.1118.

(*E*)-4-chloro-*N*-(2-(methoxyimino)-2-phenylethyl)benzamide (**3f**): White solid; mp:

1
2
3 114-115 °C; yield: 38 mg, 63 %; ¹H NMR (400 MHz, CDCl₃): δ = 7.74-7.72 (m, 2H),
4 7.54-7.52 (m, 2H), 7.44-7.39 (m, 5H), 7.04 (br, 1H), 4.50 (d, *J* = 4.4 Hz, 2H), 3.92 (s,
5 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 166.1, 151.5, 137.8, 132.7, 131.4, 129.8,
6 128.9, 128.4, 128.0, 62.5, 43.4; HRMS (EI-TOF) *m/z*: [M]⁺ calcd for C₁₆H₁₅ClN₂O₂
7 302.0822; Found 302.0818.

8
9
10
11
12 (E)-4-bromo-*N*-(2-(methoxyimino)-2-phenylethyl)benzamide (**3g**): White solid; mp:
13 138-140 °C; yield: 65 mg, 94 %; ¹H NMR (400 MHz, CDCl₃): δ = 7.67-7.64 (m, 2H),
14 7.59-7.51 (m, 4H), 7.45-7.37 (m, 3H), 7.05 (s, 1H), 4.49 (d, *J* = 4.8 Hz, 2H), 3.92 (s,
15 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 166.2, 151.5, 133.1, 131.8, 131.4, 129.8,
16 128.6, 128.4, 128.0, 126.3, 62.5, 43.4; HRMS (EI-TOF) *m/z*: [M]⁺ calcd for
17 C₁₆H₁₅BrN₂O₂ 346.0317; Found 346.0316.

18
19
20
21
22
23 methyl (E)-4-((2-(methoxyimino)-2-phenylethyl)carbamoyl)benzoate (**3h**): White
24 solid; mp: 159-161 °C; yield: 56 mg, 86 %; ¹H NMR (400 MHz, CDCl₃): δ = 8.11 (d,
25 *J* = 8.0 Hz, 2H), 7.85 (d, *J* = 8.4 Hz, 2H), 7.55-7.53 (m, 2H), 7.44-7.38 (m, 3H), 7.14
26 (br, 1H), 4.52 (d, *J* = 4.2 Hz, 2H), 3.94 (s, 3H), 3.93 (s, 3H); ¹³C NMR (100 MHz,
27 CDCl₃): δ = 166.3, 166.2, 151.4, 138.2, 132.8, 131.4, 129.9, 129.8, 128.4, 128.0,
28 127.1, 62.5, 52.4, 43.4; HRMS (EI-TOF) *m/z*: [M]⁺ calcd for C₁₈H₁₈N₂O₄ 326.1267;
29 Found 326.1274.

30
31
32
33
34
35 (E)-*N*-(2-(methoxyimino)-2-phenylethyl)-2-methylbenzamide (**3i**): White solid; mp:
36 109-110 °C; yield: 47 mg, 83 %; ¹H NMR (400 MHz, CDCl₃): δ = 7.56-7.54 (m, 2H),
37 7.45-7.39 (m, 3H), 7.35-7.29 (m, 2H), 7.21-7.18 (m, 2H), 6.51 (br, 1H), 4.51 (d, *J* =
38 5.2 Hz, 2H) 3.88 (s, 3H), 2.39 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 169.7, 151.9,
39 136.2, 136.1, 131.4, 131.0, 130.0, 129.7, 128.4, 128.1, 126.9, 125.8, 62.4, 43.1, 19.8;
40 HRMS (EI-TOF) *m/z*: [M]⁺ calcd for C₁₇H₁₈N₂O₂ 282.1368; Found 282.1364.

41
42
43
44
45
46 (E)-*N*-(2-(methoxyimino)-2-phenylethyl)-3-methylbenzamide (**3j**): White solid; mp:
47 105-107 °C; yield: 53 mg, 94 %; ¹H NMR (400 MHz, CDCl₃): δ = 7.62 (s, 1H),
48 7.55-7.52 (m, 3H), 7.42-7.30 (m, 5H), 7.03 (br, 1H), 4.50 (d, *J* = 4.4 Hz, 2H), 3.92 (s,
49 3H), 2.39 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 167.4, 151.8, 138.5, 134.3, 132.3,
50 131.5, 129.7, 128.5, 128.4, 128.0, 127.9, 123.9, 62.4, 43.3, 21.4; HRMS (EI-TOF)
51 *m/z*: [M]⁺ calcd for C₁₇H₁₈N₂O₂ 282.1368; Found 282.1364.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

(*E*)-*N*-(2-(methoxyimino)-2-phenylethyl)-2,4-dimethylbenzamide (**3k**): White solid; mp: 94-96 °C; yield: 31 mg, 52 %; ¹H NMR (400 MHz, CDCl₃): δ = 7.55-7.53 (m, 2H), 7.44-7.36 (m, 3H), 7.25 (d, *J* = 8.0 Hz, 1H), 7.02 (s, 1H), 7.00 (d, *J* = 8.4 Hz, 1H), 6.49 (br, 1H), 4.50 (d, *J* = 4.8 Hz, 2H), 3.88 (s, 3H), 2.37 (s, 3H), 2.32 (3H); ¹³C NMR (100 MHz, CDCl₃): δ = 169.7, 152.0, 140.1, 136.3, 133.2, 131.9, 131.4, 129.7, 128.4, 128.1, 127.1, 126.4, 62.4, 43.1, 21.3, 19.8; HRMS (EI-TOF) *m/z*: [M]⁺ calcd for C₁₈H₂₀N₂O₂ 296.1525; Found 296.1521.

(*E*)-*N*-(2-(methoxyimino)-2-phenylethyl)benzo[*d*][1,3]dioxole-5-carboxamide (**3l**): White solid; mp: 116-118 °C; yield: 49 mg, 79 %; ¹H NMR (400 MHz, CDCl₃): δ = 7.54-7.51 (m, 2H), 7.44-7.38 (m, 3H), 7.33-7.26 (m, 2H), 6.94 (br, 1H), 6.82 (d, *J* = 8.0 Hz, 1H), 6.01 (s, 2H), 4.48 (d, *J* = 4.8 Hz, 2H) 3.92 (s, 1H); ¹³C NMR (100 MHz, CDCl₃): δ = 166.4, 151.8, 150.4, 148.0, 131.5, 129.7, 128.5, 128.4, 128.0, 121.7, 108.1, 107.6, 101.7, 62.4, 43.4; HRMS (EI-TOF) *m/z*: [M]⁺ calcd for C₁₇H₁₆N₂O₄ 312.1110; Found 312.1114.

(*E*)-*N*-(2-(methoxyimino)-2-phenylethyl)-1-naphthamide (**3m**): White solid; mp: 94-96 °C; yield: 39 mg, 61%; ¹H NMR (400 MHz, CDCl₃): δ = 8.20-8.18 (m, 1H), 7.91- 7.84 (m, 2H), 7.59-7.57 (m, 3H), 7.51-7.48 (m, 2H), 7.46-7.41 (m, 4H), 6.72 (b, 1H), 4.62 (d, *J* = 5.2 Hz, 2H), 3.88 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 169.3, 152.0, 134.2, 133.7, 131.5, 130.7, 130.1, 129.7, 128.5, 128.3, 128.2, 127.1, 126.4, 125.4, 125.2, 124.8, 62.4, 43.3; HRMS (EI-TOF) *m/z*: [M]⁺ calcd for C₂₀H₁₈N₂O₂ 318.1368; Found 318.1365.

(*E*)-*N*-(2-(methoxyimino)-2-phenylethyl)-2-naphthamide (**3n**): White solid; mp: 133-135 °C; yield: 56 mg, 88%; ¹H NMR (400 MHz, CDCl₃): δ = 8.31 (s, 1H), 7.93-7.83 (m, 4H), 7.58-7.51 (m, 4H), 7.45-7.37 (3H), 7.19 (br, 1H), 4.58 (d, *J* = 4.8 Hz, 2H), 3.94 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 167.3, 151.8, 134.8, 132.7, 131.6, 129.7, 129.0, 128.5, 128.4, 128.0, 127.8, 127.7, 127.6, 126.8, 123.6, 62.5, 43.5; HRMS (EI-TOF) *m/z*: [M]⁺ calcd for C₂₀H₁₈N₂O₂ 318.1368; Found 318.1370.

(*E*)-*N*-(2-(methoxyimino)-2-phenylethyl)-1-methyl-1*H*-indole-3-carboxamide (**3o**): Yellow solid; mp: 144-146 °C; yield: 40 mg, 62%; ¹H NMR (400 MHz, CDCl₃): δ = 8.00-7.98 (m, 1H), 7.69 (s, 1H), 7.58-7.56 (m, 2H), 7.45-7.35 (m, 4H), 7.32-7.24 (m,

2H), 6.94 (b, 1H), 4.58 (d, $J = 4.8$ Hz, 2H), 3.97 (s, 3H), 3.80 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 164.7, 152.1, 137.3, 132.9, 131.7, 129.6, 128.4, 128.1, 125.2, 122.5, 121.4, 119.9, 110.7, 110.2, 62.5, 43.1, 33.3$; HRMS (EI-TOF) m/z : $[\text{M}]^+$ calcd for $\text{C}_{19}\text{H}_{19}\text{N}_3\text{O}_2$ 321.1477; Found 321.1480.

(*E*)-*N*-(2-(methoxyimino)-2-phenylethyl)furan-3-carboxamide (**3p**): White solid; mp: 102-103 °C; yield: 48 mg, 93%; ^1H NMR (400 MHz, CDCl_3): $\delta = 7.95$ (s, 1H), 7.53-7.51 (m, 2H), 7.43-7.36 (m, 4H), 6.73 (b, 1H), 6.64 (d, $J = 0.8$ Hz, 1H), 4.56 (d, $J = 4.8$ Hz), 3.91 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 162.3, 151.6, 144.8, 143.8, 131.5, 129.7, 128.4, 128.0, 122.4, 108.3, 62.4, 42.8$; HRMS (EI-TOF) m/z : $[\text{M}]^+$ calcd for $\text{C}_{14}\text{H}_{14}\text{N}_2\text{O}_3$ 258.1004; Found 258.1003.

(*E*)-*N*-(2-(methoxyimino)-2-phenylethyl)benzo[*b*]thiophene-3-carboxamide (**3q**): White solid; mp: 111-112 °C; yield: 52 mg, 80%; ^1H NMR (400 MHz, CDCl_3): $\delta = 8.34$ (d, $J = 7.6$ Hz, 1H), 7.90 (s, 1H), 7.86 (d, $J = 7.6$ Hz, 1H), 7.57-7.54 (m, 2H), 7.46-7.37 (m, 5H), 6.95 (br, 1H), 4.56 (d, $J = 4.8$ Hz, 2H), 3.92 (s, 3H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 163.6, 151.7, 140.3, 136.6, 131.9, 131.5, 129.9, 129.8, 128.5, 128.1, 125.2, 125.1, 124.1, 122.7, 62.5, 43.1$; HRMS (EI-TOF) m/z : $[\text{M}]^+$ calcd for $\text{C}_{18}\text{H}_{16}\text{N}_2\text{O}_2\text{S}$ 324.0932; Found 324.0933.

(*E*)-*N*-(2-(methoxyimino)-2-phenylethyl)-2-methyl-2-phenylpropanamide (**3r**): Yellow liquid; yield: 28 mg, 45 %; ^1H NMR (400 MHz, CDCl_3): $\delta = 7.41$ -7.36 (m, 5H), 7.33-7.23 (m, 5H), 5.83 (br, 1H), 4.24 (d, $J = 5.2$ Hz, 2H), 3.75 (s, 3H), 1.53 (s, 6H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 177.1, 152.2, 144.7, 131.3, 129.5, 128.6, 128.3, 128.1, 126.9, 126.6, 62.2, 47.0, 42.8, 26.9$; HRMS (EI-TOF) m/z : $[\text{M}]^+$ calcd for $\text{C}_{19}\text{H}_{22}\text{N}_2\text{O}_2$ 310.1681; Found 310.1682.

(*E*)-*N*-(2-(methoxyimino)-2-phenylethyl)cyclopropanecarboxamide (**3s**): Yellow solid; mp: 116-118 °C; yield: 36 mg, 78 %; ^1H NMR (400 MHz, CDCl_3): $\delta = 7.50$ -7.48 (m, 2H), 7.42-7.39 (m, 3H), 6.45 (b, 1H), 4.34 (d, $J = 4.8$ Hz, 2H), 3.90 (s, 3H), 1.46-1.40 (m, 1H), 0.99-0.95 (m, 2H), 0.77-0.72 (m, 2H); ^{13}C NMR (100 MHz, CDCl_3): $\delta = 173.4, 152.0, 131.6, 129.6, 128.3, 128.0, 62.3, 43.2, 14.7, 7.3$; HRMS (EI-TOF) m/z : $[\text{M}]^+$ calcd for $\text{C}_{13}\text{H}_{16}\text{N}_2\text{O}_2$ 232.1212; Found 232.1210.

(*E*)-*N*-(2-(*tert*-butoxyimino)-2-phenylethyl)benzamide (**3t**): Yellow solid; mp: 93-95

1
2
3 °C; yield: 50 mg, 81%; ¹H NMR (400 MHz, CDCl₃): δ = 7.81-7.79 (m, 2H), 7.66-7.64
4 (m, 2H), 7.54-7.35 (m, 6H), 7.21 (br, 1H), 4.54 (d, *J* = 4.4 Hz, 2H), 1.35 (s, 9H); ¹³C
5 NMR (100 MHz, CDCl₃): δ = 167.0, 148.8, 134.5, 131.8, 131.5, 129.4, 128.7, 128.3,
6 128.2, 126.9, 79.4, 43.6, 27.5; HRMS (EI-TOF) *m/z*: [M]⁺ calcd for C₁₉H₂₂N₂O₂
7 310.1681; Found 310.1681.

8
9
10
11
12 (*E*)-*N*-(2-(methoxyimino)-2-(*p*-tolyl)ethyl)benzamide (**3u**): White solid; mp: 92-94 °C;
13 yield: 56 mg, 99 %; ¹H NMR (400 MHz, CDCl₃): δ = 7.72-7.70 (m, 2H), 7.44-7.34
14 (m, 5H), 7.01 (br, 1H), 4.42 (d, *J* = 4.8 Hz, 2H), 3.84 (s, 1H), 2.28 (s, 1H); ¹³C NMR
15 (100 MHz, CDCl₃): δ = 167.1, 151.5, 139.9, 131.6, 129.1, 128.6, 128.5, 128.0, 127.0,
16 62.4, 43.3, 21.5; HRMS (EI-TOF) *m/z*: [M]⁺ calcd for C₁₇H₁₈N₂O₂ 282.1368; Found
17 282.1369.

18
19
20
21
22
23 (*E*)-*N*-(2-(4-fluorophenyl)-2-(methoxyimino)ethyl)benzamide (**3v**): White solid; mp:
24 128-130 °C; yield: 42 mg, 73 %; ¹H NMR (400 MHz, CDCl₃): δ = 7.80-7.77 (m, 2H),
25 7.62-7.57 (m, 2H), 7.54-7.50 (m, 1H), 7.47-7.43 (m, 2H), 7.14-7.08 (m, 2H), 6.98 (br,
26 1H), 4.52 (d, *J* = 4.8 Hz, 2H), 3.93 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 167.2,
27 163.1 (d, *J*_{CF} = 249.2 Hz), 150.6, 134.2, 131.7, 130.4 (d, *J*_{CF} = 8.3 Hz), 128.7, 127.3
28 (d, *J*_{CF} = 3.3 Hz), 127.0, 115.5 (d, *J*_{CF} = 21.5 Hz), 62.5, 43.2.; ¹⁹F NMR (376 MHz,
29 CDCl₃): δ = -110.0; HRMS (EI-TOF) *m/z*: [M]⁺ calcd for C₁₆H₁₅FN₂O₂ 286.1118;
30 Found 286.1115.

31
32
33
34
35
36
37
38 (*E*)-*N*-(2-(4-chlorophenyl)-2-(methoxyimino)ethyl)benzamide (**3w**): White solid; mp:
39 95-97 °C; yield: 28 mg, 46 %; ¹H NMR (400 MHz, CDCl₃): δ = 7.80 (d, *J* = 7.6 Hz,
40 2H), 7.55-7.52 (m, 3H), 7.46 (t, *J* = 7.2 Hz, 2H), 7.41 (d, *J* = 8.8 Hz), 7.03 (br, 1H),
41 4.52 (d, *J* = 4.8 Hz, 2H), 3.95 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 167.2, 150.7,
42 135.7, 134.2, 131.7, 129.7, 129.6, 128.7, 128.6, 127.0, 62.5, 43.1; HRMS (EI-TOF)
43 *m/z*: [M]⁺ calcd for C₁₆H₁₅ClN₂O₂ 302.0822; Found 302.0820.

44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
958
959
960
961
962
963
964
965
966
967
968
969
970
971
972
973
974
975
976
977
978
979
980
981
982
983
984
985
986
987
988
989
990
991
992
993
994
995
996
997
998
999
1000

(*E*)-*N*-(2-(4-bromophenyl)-2-(methoxyimino)ethyl)benzamide (**3x**): White solid; mp:
136-138 °C; yield: 66 mg, 95 %; ¹H NMR (400 MHz, CDCl₃): δ = 7.79-7.77 (m, 2H),
7.55-7.49 (m, 3H), 7.46-7.42 (m, 4H), 4.50 (d, *J* = 4.8 Hz, 1H), 3.92 (s, 1H); ¹³C
NMR (100 MHz, CDCl₃): δ = 167.2, 150.8, 134.2, 131.7, 131.6, 130.1, 129.8, 128.6,
127.0, 124.0, 62.5, 43.1; HRMS (EI-TOF) *m/z*: [M]⁺ calcd for C₁₆H₁₅BrN₂O₂

346.0317; Found 346.0320.

(*E*)-*N*-(2-(4-(*tert*-butyl)phenyl)-2-(methoxyimino)ethyl)benzamide (**3y**): Yellow oil; yield: 58 mg, 90 %; ¹H NMR (400 MHz, CDCl₃): δ = 7.89 (d, *J* = 8.4 Hz, 2H), 7.54-7.43 (m, 7H), 7.08 (br, 1H), 4.52 (d, *J* = 4.4 Hz, 2H), 3.93 (s, 3H), 1.32 (s, 9H); ¹³C NMR (100 MHz, CDCl₃): δ = 167.1, 152.9, 151.2, 134.4, 131.5, 128.6, 128.4, 127.9, 127.0, 125.4, 62.5, 43.3, 34.8, 31.2; HRMS (EI-TOF) *m/z*: [M]⁺ calcd for C₂₀H₂₄N₂O₂ 324.1838; Found 324.1840.

(*E*)-*N*-(2-(methoxyimino)-1,2-diphenylethyl)benzamide (**3z**): White solid; mp: 150-152 °C; yield: 48 mg, 70 %; ¹H NMR (400 MHz, CDCl₃): δ = 7.84-7.82 (m, 2H), 7.75 (br and d, *J* = 6.8 Hz, 1H), 7.53-7.37 (m, 5H), 7.32-7.19 (m, 8H), 6.12 (d, *J* = 7.6 Hz, 1H), 3.96 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 166.0, 155.1, 138.6, 134.4, 132.0, 131.6, 129.2, 128.7, 128.6, 128.2, 128.1, 128.0, 127.9, 127.1, 62.6, 57.1; HRMS (EI-TOF) *m/z*: [M]⁺ calcd for C₂₂H₂₀N₂O₂ 344.1525; Found 344.1524.

(*E*)-*N*-(3-(methoxyimino)-1-oxo-1-phenylbutan-2-yl)benzamide (**3aa**): Yellow oil; yield: 33 mg, 53 %; ¹H NMR (400 MHz, CDCl₃): δ = 8.13-8.11 (m, 2H), 7.89-7.87 (m, 2H), 7.64-7.60 (m, 1H), 7.56-7.45 (m, 6H), 6.36 (d, *J* = 7.2 Hz, 1H), 3.83 (s, 3H), 1.87 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 194.5, 153.0, 134.5, 134.1, 133.7, 132.0, 129.2, 128.7, 128.6, 127.2, 122.3, 62.0, 58.7, 11.9; HRMS (EI-TOF) *m/z*: [M]⁺ calcd for C₁₈H₁₈N₂O₃ 310.1317; Found 310.1316.

General procedure for the synthesis of 4. To a seal tube were added **3b** (0.2 mmol, 1.0 equiv), Cu(OAc)₂·H₂O (0.4 mmol, **2** equiv), and DCE (2.0 mL). The reaction mixture was stirred for 12 hours at 100 °C. The crude product was purified by silica gel chromatography (petroleum ether: ethyl acetate = 3:1) to afford the desired product **4**.

(*Z*)-*N*-(2-(methoxyimino)-2-phenylethyl)-4-methylbenzamide (**4**): White solid; mp: 135-137 °C; yield: 16 mg, 28%; ¹H NMR (400 MHz, CDCl₃): δ = 7.85-7.82 (m, 2H), 7.62 (d, *J* = 8.0 Hz, 2H), 7.40-7.38 (m, 3H), 7.22 (d, *J* = 8.0 Hz, 2H), 6.75 (br, 1H), 4.69 (d, *J* = 6.0 Hz, 2H), 4.08 (s, 3H), 2.38 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 166.9, 155.8, 142.0, 133.9, 131.4, 129.7, 129.3, 128.7, 127.0, 126.9, 62.6, 36.0, 21.5; HRMS (EI-TOF) *m/z*: [M]⁺ calcd for C₁₇H₁₈N₂O₂ 282.1368; Found 282.1367.

General procedure for the synthesis of 5. Method 1: To a seal tube were added **3b** (0.2 mmol, 1.0 equiv), CF₃COOH (0.4 mmol, 2 equiv), and H₂O (20 equiv), and DCE (2.0 mL). The reaction mixture was stirred for 12 hours at 50 °C. The crude product was purified by silica gel chromatography (petroleum ether: ethyl acetate = 3:1) to afford the desired product **5** (24 mg, 47% yield). Method 2: To a seal tube were added **3b** (0.2 mmol, 1.0 equiv) and BF₃·Et₂O (0.4 mmol, 2 equiv). Subsequently, DCE (2.0 mL) was added to this tube. The reaction mixture was stirred for 12 hours at 50 °C. The crude product was purified by silica gel chromatography (petroleum ether: ethyl acetate = 3:1) to afford the desired product **5** (27 mg, 53% yield).

4-methyl-*N*-(2-oxo-2-phenylethyl)benzamide (**5**): White solid; mp: 115-117 °C ; ¹H NMR (400 MHz, CDCl₃): δ = 8.05-8.03 (m, 2H), 7.79 (d, *J* = 8.0 Hz, 2H), 7.65 (t, *J* = 7.6 Hz, 1H), 7.53 (t, *J* = 7.6 Hz, 2H), 7.28-7.26 (m, 3H), 4.96 (d, *J* = 4.0 Hz, 2H), 2.42 (s, 3H); ¹³C NMR (100 MHz, CDCl₃): δ = 194.4, 167.4, 142.3, 134.4, 134.3, 131.0, 129.3, 129.0, 128.0, 127.2, 46.9, 21.5; HRMS (EI-TOF) *m/z*: [M]⁺ calcd for C₁₆H₁₅NO₂ 253.1103; Found 253.1099.

AUTHOR INFORMATION

Corresponding Author

*E-mail: chenwzz@zju.edu.cn

*E-mail: mcl@zju.edu.cn

Notes

The authors declare no competing financial interest.

ASSOCIATED CONTENT

Supporting Information. Spectra of ¹H and ¹³C NMR for new products and crystallographic data for **3a** and **3b**. This material is available free of charge via the Internet at <http://pubs.acs.org>.

ACKNOWLEDGMENT

Financial supports from National Natural Science Foundation of China (Nos. 21572203 and 21472140) and Zhejiang Provincial Natural Science Foundation of China (No. LZ16B020001) are gratefully acknowledged.

REFERENCES

- [1] Waldman A. J.; Ng T. L.; Wang P.; Balskus E. P. Heteroatom–Heteroatom Bond Formation in Natural Product Biosynthesis. *Chem. Rev.* **2017**, *117*, 5784-5863.
- [2] (a) Shindo, K.; Yamagishi, Y.; Okada, Y.; Kawai, H. Collismycins A and B, Novel Non-steroidal Inhibitors of Dexamethasone-glucocorticoid Receptor Binding. *J. Antibiot.* **1994**, *47*, 1072-1074. (b) Garcia, I.; Vior, N. M.; Brana, A. F.; Gonzalez-Sabin, J.; Rohr, J.; Moris, F.; Mendez, C.; Salas, J. A. Elucidating the Biosynthetic Pathway for the Polyketide-nonribosomal Peptide Collismycin A: Mechanism for Formation of the 2,2'-Bipyridyl Ring. *Chem. Biol.*, **2012**, *19*, 399-413.
- [3] Stammler, G.; Itoh, M.; Hino, I.; Watanabe, A.; Kojima, K.; Motoyoshi, M.; Koch, A.; Haden, E. Monitoring of the Sensitivity of Magnaporthe Grisea to Metominostrobin 2001-2003: No Emergence of Resistant Strains and No Mutations at Codon 143 or 129 of the Cytochrome b Gene. *J. Pestic. Sci.* **2005**, *30*, 203-208.
- [4] Anthes, J. C.; Chapman, R. W.; Richard, C.; Eckel, S.; Corboz, M.; Hey, J. A.; Fernandez, X.; Greenfeder, S.; Mcleod, R.; Sehring, S.; Rizzo, C.; Crawley, Y.; Shih, N.-Y.; Piwinski, J.; Reichard, G.; Ting, P.; Carruthers, N.; Cuss, F. M.; Billah, M.; Kreutner, W.; Egan, R. W. SCH 206272: a Potent, Orally Active Tachykinin NK1, NK2, and NK3 Receptor Antagonist. *Eur. J. Pharm.* **2002**, *450*, 191-202.
- [5] Sawada, H.; Yoshida, M.; Hagii, H.; Aoshima, K.; Kobayashi, M. Perfluoropropylation of Furans, Thiophenes, and Pyridines with Bis(heptafluorobutyl) Peroxide. *Bull. Chem. Soc. Jpn.* **1986**, *59*, 215-219.
- [6] Monguchi, Y.; Hattori, K.; Maegawa, T.; Hirota, K.; Sajiki, H. Iodobenzene Diacetate-promoted N-N and N-O Bond Formation for Pyrazolo- and Isoxazolopyrimidine Synthesis. *Heterocycles* **2009**, *79*, 669-680.
- [7] Kuram, M. R.; Kim, W. G.; Myung, K.; Hong, S. Y. Copper-Catalyzed Direct

Synthesis of 1,2,4-Oxadiazoles from Amides and Organic Nitriles by Oxidative N-O Bond Formation. *Eur. J. Org. Chem.* **2016**, 438-442.

[8] Stokes, B. J.; Vogel, C. V.; Urnezis, L. K.; Pan, M.; Driver, T. G. Intramolecular Fe(II)-Catalyzed N-O or N-N Bond Formation from Aryl Azides. *Org. Lett.* **2010**, *12*, 2884-2887.

[9] Chen C.; Andreani T.; Li H. A Divergent and Selective Synthesis of Isomeric Benzoxazoles from a Single N-Cl Imine. *Org. Lett.* **2011**, *13*, 6300-6303.

[10] Nimnual, P.; Tummatorn, J.; Thongsornkleeb, C.; Ruchirawat, S. Utility of Nitrogen Extrusion of Azido Complexes for the Synthesis of Nitriles, Benzoxazoles, and Benzisoxazoles. *J. Org. Chem.* **2015**, *80*, 8657-8667.

[11] For recent reviews on 2*H*-azirine chemistry, see: (a) Khlebnikov, A. F.; Novikov, M. S. Recent Advances in 2*H*-Azirine Chemistry. *Tetrahedron* **2013**, *69*, 3363-3401. (b) Huang, C.-Y.; Doyle, A. G. The Chemistry of Transition Metals with Three-Membered Ring Heterocycles. *Chem. Rev.* **2014**, *114*, 8153-8198.

[12] For selected reports, see: (a) Isomura, K.; Uto, K.; Taniguchi, H. Palladium(II)-Catalyzed Formation of Indoles from 2,2-Diphenyl-2*H*-azirines. *J. Chem. Soc., Chem. Commun.* **1977**, 664-665. (b) Isomura, K.; Ayabe, G. I.; Hatano, S.; Taniguchi, H. J. Evidence for Vinyl Nitrene Intermediates in the Thermal Rearrangement of 2*H*-Azirines into Indoles. *J. Chem. Soc., Chem. Comm.* **1980**, 1252-1253. (c) Chiba, S.; Hattori, G.; Narasaka, K. Rh(II)-catalyzed Isomerization of 2-Aryl-2*H*-azirines to 2,3-Disubstituted Indoles. *Chem. Lett.*, **2007**, *36*, 52-53; (d) Jana, S.; Clements, M. D.; Sharp, B. K.; Zheng, N. Fe(II)-Catalyzed Amination of Aromatic C-H Bonds via Ring Opening of 2*H*-Azirines: Synthesis of 2,3-Disubstituted Indoles. *Org. Lett.*, **2010**, *12*, 3736-3739.

[13] Nitta, M.; Kobayashi, T. Nonacarbonyliron or Pentacarbonyliron Induced Decomposition of Organic Azides and an Azirine. Novel Reduction and Carbonyl Insertion of the Complexed Nitrene Intermediate in Protic Solvents. *Bull. Chem. Soc. Jpn.* **1984**, *57*, 1035-1039.

[14] (a) Padwa, A.; Stengel, T. Transition Metal Catalyzed Ring Opening Reactions of 2-Phenyl-3-vinyl Substituted 2*H*-Azirines. *Tetrahedron Lett.* **2004**, *45*, 5991-5993; (b)

1
2
3 Padwa, A.; Stengel, T. Grubbs'- and Wilkinson-catalyzed Reactions of 2-Phenyl-3-
4 vinyl-substituted 2H-azirines. *Arkivoc* **2005**, 21-32.

5
6
7 [15] Zhou, W.; Zhang, M.; Li, H; Chen, W. One-Pot Three-Component Synthesis of
8 Enamine-Functionalized 1,2,3-Triazoles via Cu-Catalytic Azide-Alkyne Click
9 (CuAAC) and Cu-Catalyzed Vinyl Nitrene Transfer Sequence. *Org. Lett.* **2017**, *19*,
10 10-13.

11
12
13 [16] (a) Guimond, N.; Gouliaras, C.; Fagnou, K. Rhodium(III)-Catalyzed
14 Isoquinolone Synthesis: The N-O Bond as a Handle for C-N Bond Formation and
15 Catalyst Turnover. *J. Am. Chem. Soc.* **2010**, *132*, 6908-6909. (b) Rakshit, S.;
16 Grohmann, C.; Besset, T.; Glorius, F. Rh(III)-Catalyzed Directed C-H Olefination
17 Using an Oxidizing Directing Group: Mild, Efficient, and Versatile. *J. Am. Chem. Soc.*
18 **2011**, *133*, 2350-2353.

19
20
21 [17] The authors have applied a patent on the main work of this paper before the
22 preparation of the manuscript. For details, see: Chen, W.; Wu, F. CN 107382770,
23 November 24, 2017.

24
25 [18] (a) Ren, S.; Song, S.; Ye, L.; Feng, C.; Loh, T.-P. Copper-catalyzed
26 Oxyamination of Electron-deficient Alkenes with *N*-Acyloxyamines. *Chem. Commun.*
27 **2016**, *52*, 10373-10376. (b) Wang, W.; Peng, X.; Wei, F.; Tung, C.-H.; Xu Z. Copper(I)
28 -Catalyzed Interrupted Click Reaction: Synthesis of Diverse 5-Hetero-Functionalized
29 Triazoles. *Angew. Chem. Int. Ed.* **2016**, *55*, 649-653.

30
31 [19] (a) Shin, K.; Baek, Y.; Chang, S. Direct C-H Amination of Arenes with Alkyl
32 Azides under Rhodium Catalysis. *Angew. Chem. Int. Ed.* **2013**, *52*, 8031-8036. (b) Ali,
33 M. A.; Yao, X.; Li, G.; Lu, H. Rhodium-catalyzed Selective Mono- and Diamination
34 of Arenes with Single Directing Site "On Water". *Org. Lett.* **2016**, *18*, 1386-1389.

35
36 [20] Cui, S.; Zhang, Y.; Wang, D.; Wu, Q. Rh(III)-catalyzed C-H Activation/[4 + 3]
37 Cycloaddition of Benzamides and Vinylcarbenoids: Facile Synthesis of Azepinones.
38 *Chem. Sci.* **2013**, *4*, 3912-3916.

39
40 [21] Wrigglesworth, J. W.; Cox, B.; Lloyd-Jones, G. C.; Booker-Milburn, K. I. New
41 Heteroannulation Reactions of *N*-Alkoxybenzamides by Pd(II) Catalyzed C-H
42 Activation. *Org. Lett.*, **2011**, *13*, 5326-5329.

1
2
3 [22] Wang, Y.; Lei, X.; Tang Y. Rh(II)-catalyzed Cycloadditions of 1-Tosyl-1,2,3-
4 triazoles with 2*H*-Azirines: Switchable Reactivity of Rh-azavinylcarbene as [2C]- or
5 Aza-[3C]-synthon. *Chem. Commun.* **2015**, *51*, 4507-4510.
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60